SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria. In large-scale randomized controlled trials, SGLT2 inhibitors reduce the risk of hospitalizations for heart failure by ∼30% and often decrease the risk of cardiovascular death (1). This benefit is particularly striking in patients who have the most marked impairment of systolic function prior to treatment. In parallel, SGLT2 inhibitors also reduce the risk of end-stage renal events, including the occurrence of renal death and the need for dialysis or renal transplantation by ∼30% (2). This benefit is seen even when glomerular filtration rates are sufficiently low to abolish the glycosuric effect of these drugs. These cardiorenal benefits cannot be explained by an action of SGLT2 inhibitors to lower blood glucose, since similar effects are not seen with antidiabetes drugs that have greater antihyperglycemic actions. Additionally, they cannot be ascribed to a natriuretic action, since these drugs exert only a modest effect on plasma volume or on circulating natriuretic peptides (3). In 2016, two articles published in Diabetes Care proposed the “thrifty fuel hypothesis” to explain the cardiorenal benefits of SGLT2 inhibitors. Ferrannini et al. (4) and Mudaliar et al. (5) postulated that the action of SGLT2 inhibitors to promote ketogenesis might account for their favorable effects on the heart and kidney because enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress. However, type 2 diabetes represents a state of nutrient overabundance and not energy deprivation, as is evidenced by the enhancement of molecular pathways that promote both energy retention (e.g., through SGLT2 upregulation) and energy storage (6,7). In fact, the stressed heart already preferentially utilizes ketone bodies, …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, according to Packer M, SGLT2 inhibitors cause transcriptional changes in cells that occur during starvation, which is called “state of fasting mimicry” and include SIRT/AMPK activation and Akt/mTOR suppression (Figure 3).”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
In the citing paper
“Moreover, taking flozins causes changes similar to an ischemic state, including HIF-2α activation which stimulates erythropoiesis, and patients with higher erythrocyte count benefited most from SGLT2i therapy.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
Citations
Cites
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., Tian, B., Wagner, T., Vatner, S. F., & Sadoshima, J. (2007) · Circulation Research · doi:10.1161/01.res.0000267723.65696.4a · Cited by 1,147
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Research works printed but not linked: 1
- Balaiya, 2012, Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α, Mol Vis, 18, 114
Cited by
Items 201–247 of 247
Decision Points in the Management of Patients with Diabetic Kidney Disease
Weir (2021) · The Journal of Family Practice · doi:10.12788/jfp.0217 · Cited by 1
Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management
Miller (2021) · The Journal of Family Practice · doi:10.12788/jfp.0226 · Cited by 2
Savarimuthu, S., & Harky, A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1998458 · Cited by 1
“SGLT2i activates AMPK and stimulates its antioxidant and anti-inflammatory effects [11,12].”
BackgroundFerrannini, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa114
Lebedeva, A. Y., Koteshkova, O. M. K., Dzhioeva, O. N., Gilyarevsky, S. R., Uskach, T. M., Новикова, М. С., Orlova, Y. A., Kalashnikov, V. Y., Privalov, D. V., Ananicheva, N. A., et al. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-01-03
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225 · Cited by 3
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Shyr, Z. A., Yan, Z., Ustione, A., Egan, E. M., & Remedi, M. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.460837
Afzal, M., Al-Abbasi, F. A., Nadeem, M. S., Alshehri, S., Ghoneim, M. M., Imam, S. S., Almalki, W. H., & Kazmi, I. A. (2021) · Metabolites · doi:10.3390/metabo11110794 · Cited by 1
“of “fasting mimicry”, which stimulates the adenosine monophosphate-activated protein kinase and enzymes sirtuin 1, whose favourable anti-inflammatory actions may aid in heart function improvement [70].”
BackgroundSGLT2 Inhibition for Diabetic and Non-diabetic Kidney Disease
Yu, M., & Kim, G. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.455
“그 분 자학적 기전으로서 SGLT2 억제제 투여에 의한 adenosine monophosphate-activated protein kinase (AMPK) 및 sirtuin 1 활 성화가 제시되었다[33].”
Ashraf, H., Karbalai, S., & Jamali, R. (2021) · World Journal of Meta-Analysis · doi:10.13105/wjma.v9.i2.163
Ризвановна, А. М., Zhernakova, Y. V., Saidova, M. A., & Chazova, I. E. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-1-39-48
Špinar, J., Špinarová, L., & Vítovec, J. (2022) · Intervenční a akutní kardiologie · doi:10.36290/kar.2022.030
Indikationen von Antidiabetika jenseits der Glukosekontrolle
Hartmann, N. K., & Lehrke, M. (2023) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-023-2343-z
COVID-19, Diabetes, and Cardiovascular Disease
Duque, M. A. P., Abundes-Velasco, A., Gómez, J. C. N., Navarro, E. A. I., & Torres, E. A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_48
Sodium-Glucose Cotransporter-2 Inhibitors In Odontogenic InfectionsPreprint
Qing, C. T. Y., Nagadia, R. H., & Shum, A. K. (2023) · Research Square · doi:10.21203/rs.3.rs-3041580/v1
Sayour, A. A., Oláh, A., Ruppert, M., Barta, B. A., Horvath, E. M., Benke, K., Pólos, M., Hartyánszky, I. L., Merkely, B. P., & Radovits, T. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.4.319 · Cited by 1
Bolívar, D. F. M., & González‐Argote, J. (2023) · Salud Ciencia y Tecnología - Serie de Conferencias · doi:10.56294/sctconf2023321
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438489
Liu, X., Wang, W., & Xing, X. (2024) · The Heart Surgery Forum · doi:10.59958/hsf.7021
“The mechanisms underlying the benefits of SGLT2i are multifactorial and may involve improvement in myocardial metabolism, reduction in necrosis and fibrosis, decreased inflammation and oxidative stress, and other favorable metabolic effects [8–10].”
BackgroundAlharbi, H. A., Albasri, R. A. N., Jan, R. A., Hamood, N. A., Alqahtani, F. M. M., Alsuwaylih, M. A., Alanazi, Y. A., & Mohaini, M. A. (2024) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_164_24
Dhingra, N. K., Nwajei, E., Verma, R. K., Pfarr, E., Gąsior, T., & Verma, S. (2025) · JTCVS Open · doi:10.1016/j.xjon.2025.03.018
Rovira‐Solé, J., Santiago‐Vacas, E., Codina, P., Borrellas, A., Domingo, M., & Bayés‐Genís, A. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70002
Sinha, A. (2025) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636251356433 · Cited by 1
“12 Indications of an additional advantage can be seen when compared to other antidiabetic drugs.”
George, V., Pillai, M. H., Jacob, V., Revanth, M. P., Vasant, A., & Adnan, H. (2025) · Cureus · doi:10.7759/cureus.96616
“In the context of heart failure, SGLT2 inhibition also reduces cardiac fibrosis, causes vasodilation, and reduces inflammation [9].”
Malakapogu, P., Shyma, Z., Shetty, S., Bagchi, D., & Miraj, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00032-3
Additional file 1 of SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
Lin, C., Zhu, X., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2021) · Figshare · doi:10.6084/m9.figshare.14509557
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferović, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438492
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C. H., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Figshare · doi:10.6084/m9.figshare.20003398
Wang, H., Wang, L., Hu, F., Wang, P., Xie, Y., Li, F., & Guo, B. (2022) · Figshare · doi:10.6084/m9.figshare.21314213
SGLT2 inhibitors in polycystic kidney disease (PKD): current evidence and future perspectives
Lombardi, M., Batazzi, A., Martini, B., Mehmetaj, A., & Michelassi, S. (2025) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2025.3674
Chu, C.-H., Hsu, Y., Lee, C., Lin, L.-Y., Chuang, W.-L., Lin, H.-J., Lin, C., Cho, D., & Chang, K.-H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02026-7
Zaini, L. M., Syukri, M., Kartasasmita, A., Gondhowiardjo, T. D., & Lesmana, R. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1013249
Empagliflozin in Heart Failure and Previous Coronary Revascularization
Dhingra, N. K., Butler, J., Anker, S. D., Ferreira, J. P., Filippatos, G. S., Pfarr, E., Gąsior, T., Nordaby, M., Brueckmann, M., Pocock, S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102419
Self-citationLi, N., Liang, N., Zhang, X., & Dong, Y. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004295
Quach, H. T., Nguyen, A. T. K., Dinh, B. Q., Nguyen, T. M., Bui, H. H., Tran, T. N., Ho, T. D., Pham, A. L., & Nguyen, S. V. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345315
“At the cellular level, SGLT2 inhibition activates a fasting-like transcriptional program via AMPK and SIRT1 while suppressing Akt/mTOR signaling, promoting autophagy, reducing oxidative stress and inflammation, and preserving mitochondrial function in both the heart and kidney [14].”
Jiang, M., Zhang, F., Ren, M., Li, Z., Xie, Z., & Sun, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841513
Sagan, D., Góral, M., Siedlecki, R., Fidorowicz, D., Sergiel, K. H., Torbacka, E., Skuza, A. I., Downar-Zapolska, M., Mikłaszewicz, A., & Bednarczuk, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5476
Kuo, Y.-D., Hung, S.-J., Kuo, C.-Y., Lai, C., & Kuo, J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113445
Gomes-Filho, P. F., Valentim, C. D. S., de Andrade, C. B. V., Pinto, V. A. D. M., Cunha, R. L. D. C. D. S., de Paiva-Júnior, P. R. S., Guedes, R. R. D. C. S., Amparo, J. L. D. C., Ramos, I. P., Alves, L. L., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05723-w
“While CTR + D10 canonically activated the full-length SIRT1/PGC-1α pathway, consistent with classic fasting mimicry (Canto et al. 2010; Packer 2020a; Rodg-ers et al. 2005), HFF suppressed the classical PGC-1α protein.”
InfluentialMetabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin
Habeos, E. E., Markantes, G. Κ., Parthymou, A., Dimitropoulos, K., Habeos, G. I., Papasotiriou, M., Marangos, M. N., & Chartoumpekis, D. V. (2026) · Biomedicines · doi:10.3390/biomedicines14092016
“(d) SGLT2is might upregulate SIRT1, a nutrient deprivation signaling pathway, which could also contribute to higher EPO production [52].”
Yao, Y., Gu, Z., Hu, J., Zhu, W., & Lin, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108466
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
Zheng, X.-T., Xie, H.-Y., Wang, X.-H., Zhao, Y., Yang, J.-Y., Liu, Y.-X., Yuan, X.-L., Tang, H.-F., Jiang, Z., & Hu, H.-J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00604-3
“The resulting reduction in the insulin-to-glucagon ratio may shift systemic metabolism towards a fasting-like state characterised by lipid mobilisation and mild ketogenesis [29, 36].”
InfluentialParnasa, E., Rokach, Y., Abedat, S., Amir, O., Ben‐Dov, I. Z., & Asleh, R. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101677
Dapagliflozin Inhibits BK Polyomavirus Replication via AMPK Signaling
Li, Y., Chen, Y., Wang, J.-W., Wu, H., Hsu, H., Yang, C., & Tian, Y. (2026) · Journal of Medical Virology · doi:10.1002/jmv.71203
Metadata
- Authors
- Packer, M.
- Affiliations
- Baylor University Medical Center (US)
- Corresponding author
- Packer, Milton
- ORCID
- Packer, Milton
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-02-11
- Volume
- 43
- Issue
- 3
- Pages
- 508-511
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3008610985
- Semantic Scholar
- 18ef104bcf8e540a8930b852692198f550512f79
- Cited by
- 247
- References
- 52
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 29 · 2023: 37 · 2022: 33 · 2021: 71 · 2020: 22
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, cardiorenal benefits, cellular reprogramming, ketogenesis, ketone bodies, heart failure hospitalization, end-stage renal disease, type 2 diabetes, energy metabolism
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Fasting, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.